公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants | Wu C.-R.; Kim H.-J.; Sun C.-P.; Chung C.-Y.; Lin Y.-Y.; Tao M.-H.; Kim J.-H.; Chen D.-S.; PEI-JER CHEN | Hepatology | 2 | 3 | |
2017 | Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component | CHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A. | Journal of Clinical Oncology | 454 | 443 | |
2021 | Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer | Yu H.A.; Paz-Ares L.G.; CHIH-HSIN YANG ; Lee K.H.; Garrido P.; Park K.; Kim J.-H.; Lee D.H.; Mao H.; Wijayawardana S.R.; Gao L.; Hozak R.R.; Chao B.H.; Planchard D. | Clinical Cancer Research | 34 | 30 | |
2021 | Radiofrequency ablation of benign thyroid nodules: Recommendations from the Asian conference on tumor ablation task force | Ha E.J.; Baek J.H.; Che Y.; Chou Y.-H.; Fukunari N.; Kim J.-H.; Lin W.-C.; My L.T.; Na D.G.; Quek L.H.H.; MING-HSUN WU ; Yamakado K.; Zhou J. | Ultrasonography | 32 | 28 | |
2020 | A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis | CHIH-HSIN YANG ; Cheng Y.; Murakami H.; PAN-CHYR YANG ; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M. | Journal of Thoracic Oncology | 29 | 28 | |
2019 | The relevance of docetaxel-related febrile neutropenia to patient-reported symptoms and the quality of life in Japanese, East Asian (Korean, Taiwanese), and Non-east asian patients based on post-hoc analyses of two randomized clinical trials of docetaxel with and without anti-angiogenic agent in advanced non-small cell lung cancer after progression on platinum-based chemotherapy | Omori Y.; Enatsu S.; Brnabic A.J.M.; Rajan N.; JIN-YUAN SHIH ; Kim J.-H.; Park K.; Inoue A. | Japanese Journal of Lung Cancer | 0 | 0 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 |